LYMIT-DIS

Among non‐communicable diseases Cardiovascular diseases (CVD) are the major cause of death in Europe, claiming more than 4 million people per year in the 53 member states of the WHO European Region and around 2 million in the European Union. Recent data estimate chronic CVD to cost the EU economy more than 196 billion € every year.

Among CVDs, the development of Heart Failure (HF) represents a serious health challenge, with an estimated 6.5 million patients suffering from HF in the European Union, which corresponds to the combined current population of Brussels, Madrid, and Paris. This significant health and economic burden, is expected to further increase over the next decade due to its strong links to ageing as well as Metabolic Syndrome, which currently affects up to 25% of the population in the EU.

Our collaborative research project, LYMIT-DIS, is aimed at improving diagnosis, prognosis, and development of new treatments for HF, focusing on HF with preserved Ejection Fraction (HFpEF). This type of HF with diastolic cardiac dysfunction, affects more than 50% of HF patients, notably women, and is linked to metabolic syndrome, an increasingly common condition characterized by insulin resistance, abdominal obesity, dyslipidemia, and hypertension.

The overall objective of LYMIT-DIS is to forward our understanding of the mechanisms involved in the cardiac diastolic dysfunction in HFpEF, with the aim to identify and evaluate innovative treatments to limit the cardiac impact of metabolic syndrome and to prevent the transition from cardiac dysfunction to Heart Failure.

LYMIT-DIS

Targeted Lymphatic and Microvessel Treatments in metabolic-DISease HFpEF

Réalisation Internet Bordeaux.

Contact Us

Legal mentions